12 Cheap Biotech Stocks To Buy

Published on January 25, 2023 at 10:37 am by Fatima Farooq in Hedge Funds, News

In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy.

The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector to make significant headway through developing cures for various diseases.

Some of the more famous names in the biotech space include companies like Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV). These companies have steadily been making a name for themselves by producing medical cures and vaccines. Consequently, biotech stocks began soaring last year. According to a Wall Street Journal article published in August 2022, the SPDR S&P Biotech ETF, an equal-weighted fund of biotech stocks, was up by 41.4% in August from its low on May 11. Another fund, iShares Biotechnology ETF, also rose by 21.8% from its low on June 16. A comparison with the S&P 500’s performance between June and August shows that the broader benchmark index was only up by 16.9% over the same period. This representation of the biotech sector’s outperformance in the market resulted in renewed optimism among investors eyeing the sector, leading to stronger support for biotech stocks on Wall Street.

According to a Global Trends report published by the National Intelligence Council’s Strategic Futures Group in April 2021, the global bio-economy accounted for about $5 trillion, or nearly 6% of global GDP at the time. The global bio-economy refers to all activity enabled by research and innovation in the life sciences and biotech. The report also mentioned that the global bio-economy could exceed $20 trillion by 2023, based on 10%-15% annual revenue growth trends in the sector. This growth in the biotech sector is expected to arise from a more multidisciplinary and data-intensive approach to the life sciences and biotech over the next two decades. By 2023, we are already beginning to observe an increased usage of biotech by medical professionals and medical diagnostics. Personal Internet of Things (IoT) devices are also being used to collect higher volumes of health data to be used in predicting new diseases and treatment outcomes in the biotech space. As such, we can expect the sector to continue soaring in the years to come.

louis-reed-pwcKF7L4-no-unsplash

Let’s now take a look at the 12 cheap biotech stocks to buy.

Our Methodology

We scanned Insider Monkey’s database of 920 elite hedge funds and picked the top 12 biotech stocks with P/E ratios less than 20. That means the stocks mentioned in the article are the most popular cheap biotech stocks among elite hedge funds. For reference, P/E ratio for the broader biotech industry is 113, according to NYU Stern’s database.

The stocks are ranked based on their P/E ratios, from the highest to the lowest.

Note: All share prices mentioned in the article are as of January 22, 2023.

Cheap Biotech Stocks To Buy

12. Incyte Corporation (NASDAQ:INCY)

Number of Hedge Fund Holders: 39

P/E ratio as of January 22: 20.70

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company. It is based in Wilmington, Delaware.

Incyte Corporation (NASDAQ:INCY) is considered to be undervalued at present, considering it showed a 20% year-over-year product revenue growth in the third quarter of 2022. Analysts believe the stock is trading at a discount, with its P/E ratio being just over 20 and with revenue growing by $38 million year-over-year by November 2022.

Incyte Corporation (NASDAQ:INCY) had 39 hedge funds long its stock in the third quarter of 2022, with a total stake value of $3.4 billion.

11. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Number of Hedge Fund Holders: 27

P/E ratio as of January 22: 19.26

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage biotech company. It is based in Plymouth Meeting, Pennsylvania.

David Amsellem at Piper Sandler holds an Overweight rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares as on January 4. Piper Sandler set a price target of $70. This is an increase from their previous target of $62, meaning analysts currently see huge upside potential in the stock.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) was found among the 13F holdings of 27 hedge funds in the third quarter. Their total stake value was $338 million.

10. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 80

P/E ratio as of January 22: 19.09

AbbVie Inc. (NYSE:ABBV) is a biotech company based in North Chicago, Illinois. The company’s products include Humira, a therapy for autoimmune and intestinal Behçet’s diseases.

A Buy rating was reiterated on AbbVie Inc. (NYSE:ABBV) shares on January 5 by Truist analyst Robyn Karnauskas.

In the broader healthcare sector, AbbVie Inc. (NYSE:ABBV) is trading at a discounted valuation compared to its competitors, such as Johnson & Johnson.

In total, 80 hedge funds were long AbbVie Inc. (NYSE:ABBV) in the third quarter, with a total stake value of $1.9 billion.

9. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Holders: 47

P/E ratio as of January 22: 17.71

United Therapeutics Corporation (NASDAQ:UTHR) develops and commercializes products to treat chronic diseases in the US and worldwide. It is based in Silver Spring, Maryland.

On December 6, United Therapeutics Corporation (NASDAQ:UTHR) was initiated with a Buy rating at UBS by analyst Ashwani Verma.

United Therapeutics Corporation (NASDAQ:UTHR) is currently trading at an attractively low valuation with a P/E ratio of 17.71 and a PEG ratio of 1.11. The company’s PEG ratio is based on the consensus expected earnings growth of 13% annually over the next three to five years.

Our hedge fund data shows 47 hedge funds long United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter. Their total stake value was $2.5 billion.

8. Exelixis, Inc. (NASDAQ:EXEL)

Number of Hedge Fund Holders: 35

P/E ratio as of January 22: 17.43

Exelixis, Inc. (NASDAQ:EXEL) is a biotech company based in California, US. The company is focused on oncology and works to develop medicines for cancers.

An Outperform rating was reiterated on Exelixis, Inc. (NASDAQ:EXEL) shares on January 21 by analyst Andy Hsieh at William Blair.

The average analyst price target on Exelixis, Inc. (NASDAQ:EXEL) stands at $25, representing an upside potential of 50%. The company has a market capitalization of $5.3 billion, making it an attractive buy relative to its peers.

There were 35 funds long Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, with a total stake value of $671 million.

7. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 43

P/E ratio as of January 22: 15.09

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotech company based in the US. The company invents and commercializes medicines to treat a range of diseases across the globe.

JPMorgan’s Chris Schott upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares from Neutral to Overweight on January 21.

Between April and August of 2022, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) saw a share price decline of 20%. The stock has since recovered to its current share price of $722, and analysts on Wall Street expect it to continue upwards as 2023 progresses. JPMorgan, for instance, currently holds a price target of $850 on the stock. Coupled with the company’s P/E ratio of 15.09, this makes the stock seem to be trading at a discount to its true potential.

Citadel Investment Group was the largest stakeholder in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, holding 603,600 shares worth $415.8 million. In total, 43 hedge funds were long the stock, with a total stake value of $1.3 billion.

Bronte Capital, an investment management company, mentioned Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its third-quarter 2022 investor letter. Here’s what the firm said:

“There have been some bright spots in our long book. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a major position and a stock we wrote up in our June 2021 letter, has been one of the best performing stocks in the S&P 500 this year. Alas it has not been enough to offset some of our weaker stocks, let alone our overweight exposure to the UK (and Europe) which have suffered from both stock and currency weakness. We do not think we are bad at picking stocks on the long side and hope – reasonably we think – for better relative results in the future. Prior to COVID, our longs were markedly better than the index. Unfortunately, if you look at our long book this quarter and since the onset of the COVID pandemic, there is scant evidence that we have added any value by picking stocks to go long.”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), like BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV), is a highly popular biotech stock today, as evidenced by the number of hedge funds piling into it.

6. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Holders: 70

P/E ratio as of January 22: 14.32

Biogen Inc. (NASDAQ:BIIB) develops and delivers therapies for neurological and neurodegenerative diseases. The company is based in Cambridge, Massachusetts.

Brian Abrahams at RBC Capital holds an Outperform rating on Biogen Inc. (NASDAQ:BIIB) shares as of January 10.

Compared to the company’s current share price of $285.77, RBC Capital analysts hold a price target of $362 on the stock, representing how undervalued the market views Biogen Inc. (NASDAQ:BIIB) to be.

There were 70 hedge funds long Biogen Inc. (NASDAQ:BIIB) in the third quarter. Their total stake value was $3.7 billion.

ClearBridge Investments, an investment management company, mentioned Biogen Inc. (NASDAQ:BIIB) in its third-quarter 2022 investor letter. Here’s what the firm said:

“Biogen Inc. (NASDAQ:BIIB) was the leading contributor among several biopharma names, boosted by positive, pivotal clinical data for its next-generation Alzheimer’s treatment Lecanemab. In a pivotal trial, the drug proved safe and efficacious in slowing progression of Alzheimer’s disease.”

Biogen Inc. (NASDAQ:BIIB), like Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV), is a biotech stock with immense growth potential.

Click to continue reading and see 5 Cheap Biotech Stocks To Buy.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up